
Opinion|Videos|June 16, 2025
Remaining unmet needs in diverse populations with mHSPC
Author(s)Quoc-Dien Trinh, MD, MPH
Enhancing minority enrollment in clinical trials and utilizing real-world data improves drug safety and efficacy for mHSPC treatments.
Advertisement
Episodes in this series

Future Research Directions
Key Themes:
- There is a need for continued efforts to improve minority enrollment in clinical trials.
- The importance of real-world evidence to complement trial data is growing.
- A combined approach should use trial and real-world data for comprehensive assessment.
- Future research should prioritize diversity and representation.
Key Points for Physicians:
- Stay informed about evolving evidence from clinical trials and real-world data.
- Support efforts to improve diversity in research.
- Consider contributing to real-world evidence generation.
- Recognize limitations in current evidence while awaiting more comprehensive data.
Notable Insights: Real-world evidence provides an important complement to clinical trial data, particularly for understanding outcomes in traditionally underrepresented populations.
Clinical Significance: Ongoing commitment to inclusive research and evidence generation will improve the quality and equity of prostate cancer care, particularly for populations historically underrepresented in clinical trials.
Advertisement
Related to this article

Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.

The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.

American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.

Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.

Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.

A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5


